Source:http://linkedlifedata.com/resource/pubmed/id/11154237
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2001-1-29
|
| pubmed:abstractText |
We have previously shown that the keys to high-level nontoxic chimerism in syngeneic models are stem cell toxic, nonmyelotoxic host treatment as provided by 100-cGy whole-body irradiation and relatively high levels of marrow stem cells. This approach was unsuccessful in H-2 mismatched B6.SJL to BALB/c marrow transplants, but with tolerization, stable multilineage chimerism was obtained. Ten million B6.SJL spleen cells were infused intravenously into BALB/c hosts on day -10 and (MR-1) anti-CD40 ligand monoclonal antibody (mAb) injected intraperitoneally at varying levels on days -10, -7, -3, 0, and +3 and the BALB/c mice irradiated (100 cGy) and infused with 40 million B6.SJL/H-2 mismatched marrow cells on day 0. Stable multilineage chimerism at levels between 30% to 40% was achieved in the great majority of mice at 1.6 mg anti-CD40 ligand mAb per injection out to 64 weeks after transplantation, without graft-versus-host disease. The transplanted mice were also tolerant of donor B6.SJL, but not third-party CBA/J skin grafts at 8 to 9 and 39 to 43 weeks after marrow transplantation. These data provide a unique model for obtaining stable partial chimerism in H-2 mismatched mice, which can be applied to various clinical diseases of man such as sickle cell anemia, thalassemia, and autoimmune disorders.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
97
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
557-64
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:11154237-Animals,
pubmed-meshheading:11154237-Antibodies, Monoclonal,
pubmed-meshheading:11154237-Blood Group Incompatibility,
pubmed-meshheading:11154237-Bone Marrow Transplantation,
pubmed-meshheading:11154237-CD40 Ligand,
pubmed-meshheading:11154237-Cell Transplantation,
pubmed-meshheading:11154237-Dose-Response Relationship, Drug,
pubmed-meshheading:11154237-Graft Survival,
pubmed-meshheading:11154237-Graft vs Host Disease,
pubmed-meshheading:11154237-H-2 Antigens,
pubmed-meshheading:11154237-Immune Tolerance,
pubmed-meshheading:11154237-Immunization,
pubmed-meshheading:11154237-Immunophenotyping,
pubmed-meshheading:11154237-Male,
pubmed-meshheading:11154237-Mice,
pubmed-meshheading:11154237-Models, Animal,
pubmed-meshheading:11154237-Spleen,
pubmed-meshheading:11154237-Time Factors,
pubmed-meshheading:11154237-Transplantation, Homologous,
pubmed-meshheading:11154237-Transplantation Chimera,
pubmed-meshheading:11154237-Whole-Body Irradiation
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Allogeneic chimerism with low-dose irradiation, antigen presensitization, and costimulator blockade in H-2 mismatched mice.
|
| pubmed:affiliation |
Cancer Center, University of Massachusetts Medical Center, Worcester, MA 01655, USA. peter.quesenberry@umassmed.edu
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|